MRI in Renal Tumors

Advanced MRI in Renal Tumors.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02325921

Enrollment

Registered

2014-12-25

Start date

2014-10-31

Completion date

2018-06-30

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma

Keywords

Magnetic Resonance Imaging, Diffusion Weighted MRI, Diffusion Tensor Imaging

Brief summary

Diagnostic imaging for renal masses of unknown nature using conventional imaging modalities such as 3 phase contrast-enhanced computed tomography (CT) is not always conclusive. After (partial) nephrectomy, 10-20 % of the resected tumors show benign histology which could not be identified on diagnostic imaging. With improved imaging techniques available, leading to improvements in characterisation of renal tumors, the number of unnecessary resections may be reduced. The objective of this study is to assess the ability to discriminate oncocytoma from RCC based on the ADC distribution parameters with addition of, tumor volume, and patient demographic characteristics.

Interventions

DEVICEMagnetic Resonance Imaging

One MRI examination, diagnostic scanning protocol as used for renal tumours with additional diffusion weighted sequences, but without contrast enhancement.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Radiologic diagnosis of renal tumor based on previous ultrasonography, CT or MRI examinations. * Signed Institutional Review Board (IRB) approved informed consent form. * Being at least 18 years of age. * Histopathologically confirmed renal tumor diagnosis.

Exclusion criteria

* Relative contra indications for MRI (metal device/foreign bodies, claustrophobia); * Active renal or perirenal infection; * Minor and/or incapacitated adult.

Design outcomes

Primary

Measure	Time frame
Discriminating malignant from benign renal lesions using Apparent Diffusion Coefficient (ADC, a metric obtained by diffusion weighted MRI) value distribution analysis.	45 months

Secondary

Measure	Time frame
Additional value of tumor volume and patient characteristics to discriminate malignant from benign renal lesions.	45 months

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026